FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, US; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, US; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, CA; 5Chang Gung University College of Medicine, Taoyuan, TW; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, DE; 8Department of Dermatology and Population Health Sciences, King’s College London, London, UK; 9Ada West Dermatology, St Luke's Children's Hospital, Idaho, US; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney AU; 11Eli Lilly and Company, Indianapolis, Indiana,US; 12Almirall R&D, S.A., Barcelona, ES; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, US
202PDF: 46 -
